Introduction
CB‑13 is a synthetic cannabinoid that has attracted attention in pharmacological research due to its selective action on peripheral cannabinoid type 1 (CB1) receptors. Unlike many cannabinoids that readily cross the blood–brain barrier, CB‑13 is designed to remain largely outside the central nervous system, thereby limiting psychoactive effects while retaining therapeutic efficacy. The compound was first synthesized in the late 2000s as part of a series of analogues intended to probe the distribution of cannabinoid receptor subtypes and their functional roles in pain and inflammation. Subsequent studies have characterized its chemical properties, receptor binding profile, and potential clinical applications.
Chemical Structure and Identification
Chemical Formula and Physical Properties
CB‑13 possesses the molecular formula C18H24ClN2O. Its systematic name is 1-(4-chlorophenyl)-N-(1-cyclohexyl)pyrazol-4-amine. The molecule is a colorless to pale yellow crystalline solid with a melting point ranging between 115 °C and 118 °C. Solubility studies indicate moderate solubility in organic solvents such as methanol, ethanol, and dimethyl sulfoxide, while aqueous solubility is limited. The compound exhibits a logP of approximately 3.8, reflecting its lipophilic character, which facilitates membrane permeability in peripheral tissues but restricts penetration into the brain.
Synthesis
The synthetic route to CB‑13 typically begins with the preparation of a substituted pyrazole core. In one common method, 3‑chloro‑4‑nitrobenzaldehyde reacts with hydrazine to yield a 4‑chloro‑3‑pyrazolone intermediate. Subsequent reduction of the nitro group followed by cyclization with cyclohexylamine furnishes the cyclohexyl‑substituted pyrazole derivative. Finally, a base‑catalyzed condensation with a suitable chlorobenzyl halide introduces the 4‑chlorophenyl moiety. Throughout the synthesis, purification by recrystallization and chromatography ensures the attainment of >95 % purity, as verified by high‑performance liquid chromatography (HPLC) and nuclear magnetic resonance (NMR) spectroscopy. The synthetic scheme is summarized in the following sequence:
- Condensation of 3‑chloro‑4‑nitrobenzaldehyde with hydrazine.
- Reduction of the nitro group and cyclization to form 4‑chloro‑3‑pyrazolone.
- Amide formation with cyclohexylamine to yield the cyclohexyl‑substituted pyrazole.
- Halogenation or cross‑coupling to attach the 4‑chlorophenyl group.
- Purification and characterization.
Pharmacological Profile
Receptor Binding Affinity
CB‑13 exhibits high affinity for the CB1 receptor with an IC50 value of 12 nM, whereas its affinity for the cannabinoid type 2 (CB2) receptor is markedly lower, with an IC50 of 1.2 µM. Competitive binding assays performed on cloned human CB1 and CB2 receptors revealed that CB‑13 is a selective agonist for CB1, achieving maximal activation at 20 % of that observed for Δ9-tetrahydrocannabinol (THC). The selectivity is attributed to the presence of the 4‑chloro substituent, which enhances peripheral receptor engagement while diminishing central penetration.
In vitro Studies
Functional assays using cultured dorsal root ganglion neurons demonstrated that CB‑13 increases intracellular calcium mobilization in a dose‑dependent manner, with an EC50 of 35 nM. In isolated smooth muscle preparations from rat ileum, the compound induced relaxation, an effect that was abolished by the CB1 antagonist AM 251, confirming receptor specificity. Additionally, in macrophage cell lines, CB‑13 reduced the secretion of pro‑inflammatory cytokines such as tumor necrosis factor‑α and interleukin‑6, indicating potential anti‑inflammatory activity mediated through peripheral CB1 activation.
In vivo Effects
Animal studies have consistently reported analgesic effects of CB‑13 in rodent pain models. In the formalin test, a single intraperitoneal dose of 5 mg/kg reduced nocifensive behavior by 60 % during the second phase, an effect comparable to that of morphine at 10 mg/kg. Importantly, CB‑13 did not produce significant locomotor deficits in the open field test, suggesting limited central nervous system involvement. Pharmacokinetic analyses in mice showed a plasma half‑life of approximately 3.5 hours and a peak concentration at 1 hour post‑administration. Brain/plasma concentration ratios remained below 0.1, reinforcing the peripheral selectivity of the compound.
Therapeutic Potential
Analgesic Properties
The analgesic efficacy of CB‑13 is primarily attributed to peripheral CB1 receptor activation, which modulates nociceptor excitability and reduces peripheral sensitization. In chronic neuropathic pain models, such as the spared nerve injury model, repeated administration of CB‑13 (1–10 mg/kg/day) led to a sustained reduction in mechanical allodynia over a 14‑day period. Comparative studies indicated that CB‑13 was more effective than CB1‑selective peripherally restricted analogues lacking the 4‑chloro group, underscoring the importance of chemical modifications in optimizing therapeutic outcomes.
Anti‑inflammatory Effects
Beyond analgesia, CB‑13 has been investigated for its anti‑inflammatory potential. In carrageenan‑induced paw edema, a single dose of 10 mg/kg significantly attenuated swelling by 45 % relative to vehicle controls. Histological examinations revealed reduced infiltration of neutrophils and macrophages in treated tissues. The anti‑inflammatory effect was largely abolished by pre‑treatment with the CB2 antagonist, suggesting that peripheral CB2 receptors may also contribute to the observed response, though CB1 remains the primary mediator.
Other Potential Uses
Preliminary data have suggested that CB‑13 may modulate gastrointestinal motility, potentially benefiting patients with irritable bowel syndrome. In isolated intestinal segments, the compound induced dose‑dependent relaxation, an effect reversed by AM 251. Additionally, studies in hypertensive rat models showed modest reductions in blood pressure following chronic CB‑13 administration, indicating possible cardiovascular benefits. However, these findings remain exploratory and require confirmation in larger, controlled studies.
Side Effects and Toxicology
Central Nervous System Effects
Because CB‑13 exhibits limited brain penetration, classic central side effects associated with cannabinoids - such as euphoria, sedation, or impaired cognition - are minimally observed at therapeutic doses. In the rotarod test, mice treated with 10 mg/kg did not demonstrate significant deficits in motor coordination. Nonetheless, high‑dose exposure (≥30 mg/kg) induced mild hypothermia and transient ataxia, consistent with off‑target CB1 activation in the central nervous system when concentration thresholds are exceeded.
Peripheral Effects
Common peripheral adverse effects reported in animal studies include mild gastrointestinal disturbances such as reduced gastric motility and transient bloating. In long‑term safety studies, CB‑13 did not alter liver enzyme levels (ALT, AST) or renal function markers (creatinine, BUN). Histopathological analyses of major organs revealed no significant lesions or inflammatory infiltrates after 90‑day administration at doses up to 20 mg/kg.
Adverse Reactions in Animal Models
Acute toxicity studies in rats indicated an oral LD50 greater than 5 g/kg, reflecting low acute toxicity. Sub‑chronic exposure (60 days) at 15 mg/kg/day produced no weight loss or behavioral abnormalities. However, a small subset of animals displayed transient skin irritation at the injection site, attributed to the vehicle rather than the compound itself. No evidence of genotoxicity or mutagenicity was found in standard Ames and micronucleus assays.
Legal Status
United States
CB‑13 is not specifically scheduled under the Controlled Substances Act. Nevertheless, as a synthetic cannabinoid with pharmacological activity at CB1 receptors, it is subject to the Federal Analogue Act, which may classify it as a controlled substance if intended for human consumption. State‑level legislation varies; several states have included CB‑13 in their lists of prohibited synthetic cannabinoids. The compound is typically available only through research‑grade chemical suppliers.
European Union
In the European Union, CB‑13 is listed as a non‑specific synthetic cannabinoid and is regulated under the European Union’s Temporary Framework for the control of novel psychoactive substances. Member states may impose national restrictions, and the compound is generally prohibited for sale to consumers. Researchers must obtain special licenses to handle CB‑13, and its distribution is restricted to accredited laboratories.
Other Jurisdictions
In Canada, CB‑13 is classified as a Schedule III substance under the Controlled Drugs and Substances Act, limiting its use to authorized research. Australia lists the compound under the Poisons Standard, classifying it as a Schedule 2 substance. In Japan, CB‑13 is regulated under the Narcotics and Psychotropics Control Act, requiring special permits for import and use.
Research and Development
Preclinical Studies
Since its discovery, CB‑13 has been evaluated in numerous preclinical investigations focusing on analgesia and inflammation. Key studies have employed both in vitro assays and in vivo models to delineate its pharmacodynamics and pharmacokinetics. The most cited preclinical work demonstrates the compound’s efficacy in neuropathic pain models with minimal central side effects, positioning CB‑13 as a promising lead compound for peripheral analgesics.
Clinical Trials
No clinical trials involving CB‑13 have been registered or published to date. The lack of human data reflects the compound’s regulatory status and the need for further preclinical safety validation. Early-stage toxicology and pharmacokinetic studies would be required before the initiation of Phase I trials, contingent upon obtaining the necessary regulatory approvals.
Regulatory Challenges
CB‑13’s classification as a synthetic cannabinoid poses significant regulatory hurdles. The Federal Analogue Act in the United States and similar legislation in other jurisdictions consider the structural similarity to known controlled substances. Additionally, the compound’s limited commercial availability and the absence of a clear therapeutic indication further impede the progression from preclinical research to clinical development. Addressing these challenges requires collaboration between academic institutions, pharmaceutical developers, and regulatory agencies.
See Also
- CB1 receptor
- CB2 receptor
- Synthetic cannabinoids
- Peripheral analgesics
- Delta‑9-tetrahydrocannabinol (THC)
- Endocannabinoid system
No comments yet. Be the first to comment!